Form 8-K - Current report:
SEC Accession No. 0001213900-24-085543
Filing Date
2024-10-04
Accepted
2024-10-04 16:05:28
Documents
17
Period of Report
2024-10-03
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0216746-8k_oruka.htm   iXBRL 8-K 30564
2 AMENDED AND RESTATED EMPLOYMENT LETTER AGREEMENT BY AND BETWEEN THE COMPANY AND ea021674601ex10-1_oruka.htm EX-10.1 63639
3 AMENDED AND RESTATED EMPLOYMENT LETTER AGREEMENT BY AND BETWEEN THE COMPANY AND ea021674601ex10-2_oruka.htm EX-10.2 58195
4 GRAPHIC ex10-1_001.jpg GRAPHIC 6156
5 GRAPHIC ex10-2_001.jpg GRAPHIC 6156
  Complete submission text file 0001213900-24-085543.txt   378427

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE orka-20241003.xsd EX-101.SCH 3012
7 XBRL LABEL FILE orka-20241003_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE orka-20241003_pre.xml EX-101.PRE 22357
19 EXTRACTED XBRL INSTANCE DOCUMENT ea0216746-8k_oruka_htm.xml XML 3678
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

IRS No.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22873 | Film No.: 241354944
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)